Relay Therapeutics, Inc.
RLAY
$3.26
$0.061.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -60.83% | -61.22% | 3,637.58% | 2,873.65% | 1,749.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.83% | -61.22% | 3,637.58% | 2,873.65% | 1,749.82% |
| Cost of Revenue | -3.35% | 2.66% | 9.24% | 18.89% | 34.31% |
| Gross Profit | -1.53% | -8.33% | 2.12% | -6.47% | -24.51% |
| SG&A Expenses | 2.11% | 2.80% | 4.41% | 8.19% | 13.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.29% | 2.69% | 8.27% | 16.65% | 29.66% |
| Operating Income | -1.65% | -7.16% | 0.81% | -6.83% | -22.02% |
| Income Before Tax | 1.25% | -5.90% | 6.27% | -1.99% | -17.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.25% | -5.90% | 6.27% | -1.99% | -17.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.25% | -5.90% | 6.27% | -1.99% | -17.72% |
| EBIT | -1.65% | -7.16% | 0.81% | -6.83% | -22.02% |
| EBITDA | -1.62% | -7.14% | 1.03% | -6.59% | -21.94% |
| EPS Basic | 14.13% | 2.54% | 13.08% | 5.78% | -7.58% |
| Normalized Basic EPS | 12.21% | 2.68% | 11.30% | 5.86% | -5.60% |
| EPS Diluted | 14.13% | 2.54% | 13.08% | 5.78% | -7.58% |
| Normalized Diluted EPS | 12.21% | 2.68% | 11.30% | 5.86% | -5.60% |
| Average Basic Shares Outstanding | 16.58% | 8.73% | 7.53% | 8.16% | 9.17% |
| Average Diluted Shares Outstanding | 16.58% | 8.73% | 7.53% | 8.16% | 9.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |